pal biotech and it consultants, LLC

103 cedar run
rensselaer, new york 12144

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 17, 2014

NYS DOS ID#
4515652

County
RENSSELAER

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - PAL BIOTECH AND IT CONSULTANTS, LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Four Credit Repair Agencies Accused Of Misleading Customers, Charging Illegal Fees
    By Ashlee Kieler - Tuesday Jun 27, 2017

    Four different “credit repair” operations have been ordered to pay a total of more than $2 million in penalties for allegedly tricking people into thinking their bad credit could be easily fixed.The Consumer Financial Protection Bureau announced today that it filed complaints and proposed judgments against Prime Credit, LLC, IMC Capital, LLC, Commercial Credit Consultants, and Park View Law, …

    Source: The Consumerist
  • What Steps Should NY Biotech Take in 2018? Share Your View on Dec. 11
    By Ben Fidler - Monday Nov 20, 2017

    Change takes time. Particularly in the life sciences, where a single drug’s journey from idea to market can consist of more than a decade of small, yet critical steps. For New York, then, aspirations to become a region known for its biotech industry are—and always have been—a long game in which every year and bit […]

    Source: Xconomy VC, Deals, & Startups Feed
  • FDA clears cheaper biotech drug copycats, but buying them isn’t easy
    By Cynthia Koons, Anna Edney and Susan Decker - Tuesday Sep 19, 2017

    In 2016, Roche sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the Food and Drug Administration approved what’s expected to be a less-expensive version. Patients and insurers won’t be able to count the savings any time soon. Of seven biosimilar drugs the FDA has cleared since the first approval of one of the drugs in 2015, only three are available for sale. The rest are tied up in legal disputes that can block the cheaper versions for years. “Basically, there’s a gazillion patents,” said Gillian Woollett, senior vice president at the consulting firm Avalere Health and an expert on the drugs.

    Source: SFGATE.com: Business and Technology News
  • Alexandria Debuts NY’s Latest Bio Incubator With 13 Startups in Tow
    By Ben Fidler - Tuesday Jun 13, 2017

    A new startup incubator has just opened in Manhattan this morning, adding to a growing list of facilities meant to help support seedling New York City biotechs. LaunchLabs, first announced by Alexandria Real Estate Equities a year ago, officially opened its doors and revealed the 13 startups that will grow there. LaunchLabs is a 15,000-square-foot […]

    Source: Xconomy VC, Deals, & Startups Feed